Literature DB >> 33718153

RBM10 Regulates Tumor Apoptosis, Proliferation, and Metastasis.

Yingshu Cao1, Xin Di1, Qinghua Zhang1, Ranwei Li2, Ke Wang1.   

Abstract

The RNA-binding motif protein 10 (RBM10) is involved in alternative splicing and modifies mRNA post-transcriptionally. RBM10 is abnormally expressed in the lung, breast, and colorectal cancer, female genital tumors, osteosarcoma, and other malignant tumors. It can inhibit proliferation, promote apoptosis, and inhibit invasion and metastasis. RBM10 has long been considered a tumor suppressor because it promotes apoptosis through the regulation of the MDM2-p53 negative feedback loop, Bcl-2, Bax, and other apoptotic proteins and inhibits proliferation through the Notch signaling and rap1a/Akt/CREB pathways. However, it has been recently demonstrated that RBM10 can also promote cancer. Given these different views, it is necessary to summarize the research progress of RBM10 in various fields to reasonably analyze the underlying molecular mechanisms, and provide new ideas and directions for the clinical research of RBM10 in various cancer types. In this review, we provide a new perspective on the reasons for these opposing effects on cancer biology, molecular mechanisms, research progress, and clinical value of RBM10.
Copyright © 2021 Cao, Di, Zhang, Li and Wang.

Entities:  

Keywords:  RNA-binding motif protein 10 (RBM10); RNA-binding motif protein 5 (RBM5); RNA-binding motif protein 6 (RBM6); alternative splicing; apoptosis; numb; p53; proliferation

Year:  2021        PMID: 33718153      PMCID: PMC7943715          DOI: 10.3389/fonc.2021.603932

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  81 in total

1.  Massively parallel sequencing of exons on the X chromosome identifies RBM10 as the gene that causes a syndromic form of cleft palate.

Authors:  Jennifer J Johnston; Jamie K Teer; Praveen F Cherukuri; Nancy F Hansen; Stacie K Loftus; Karen Chong; James C Mullikin; Leslie G Biesecker
Journal:  Am J Hum Genet       Date:  2010-05-06       Impact factor: 11.025

2.  An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication.

Authors:  Syed Mohd Danish Rizvi; Abdulaziz Arif A Alshammari; Waleed Abdullah Almawkaa; Abo Bakr F Ahmed; Ahmed Katamesh; Ahmed Alafnan; Tariq J Almutairi; Rakan F Alshammari
Journal:  3 Biotech       Date:  2019-02-09       Impact factor: 2.406

Review 3.  Nuclear localization signals and human disease.

Authors:  Laura M McLane; Anita H Corbett
Journal:  IUBMB Life       Date:  2009-07       Impact factor: 3.885

4.  Molecular cloning of a RNA binding protein, S1-1.

Authors:  A Inoue; K P Takahashi; M Kimura; T Watanabe; S Morisawa
Journal:  Nucleic Acids Res       Date:  1996-08-01       Impact factor: 16.971

5.  Genome-wide identification of Fas/CD95 alternative splicing regulators reveals links with iron homeostasis.

Authors:  J Ramón Tejedor; Panagiotis Papasaikas; Juan Valcárcel
Journal:  Mol Cell       Date:  2014-12-04       Impact factor: 17.970

6.  Clinical diagnostic exome evaluation for an infant with a lethal disorder: genetic diagnosis of TARP syndrome and expansion of the phenotype in a patient with a newly reported RBM10 alteration.

Authors:  Zöe Powis; Alexa Hart; Sara Cherny; Igor Petrik; Erika Palmaer; Sha Tang; Carolyn Jones
Journal:  BMC Med Genet       Date:  2017-06-02       Impact factor: 2.103

7.  RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5.

Authors:  Julie J Loiselle; Justin G Roy; Leslie C Sutherland
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

8.  Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing.

Authors:  Jiawei Zhao; Yue Sun; Yin Huang; Fan Song; Zengshu Huang; Yufang Bao; Ji Zuo; David Saffen; Zhen Shao; Wen Liu; Yongbo Wang
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

Review 9.  Recent progress in mapping the emerging landscape of the small-cell lung cancer genome.

Authors:  Kee-Beom Kim; Colin T Dunn; Kwon-Sik Park
Journal:  Exp Mol Med       Date:  2019-12-12       Impact factor: 8.718

Review 10.  Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway.

Authors:  Scott Bang; Sandeep Kaur; Manabu Kurokawa
Journal:  Int J Mol Sci       Date:  2019-12-30       Impact factor: 5.923

View more
  4 in total

1.  Integrated Bioinformatics Analysis and Validation of the Prognostic Value of RBM10 Expression in Hepatocellular Carcinoma.

Authors:  Shu-Jie Pang; Zhe Sun; Wen-Feng Lu; Hui Si-Ma; Zhi-Peng Lin; Yang Shi; Ying-Cheng Yang; Xi-Jun Zhao; Guang-Shun Yang; Guang-Zhi Jin; Ning Yang
Journal:  Cancer Manag Res       Date:  2022-03-04       Impact factor: 3.989

2.  The Inflamm-Aging Model Identifies Key Risk Factors in Atherosclerosis.

Authors:  Yudan He; Yao Chen; Lilin Yao; Junyi Wang; Xianzheng Sha; Yin Wang
Journal:  Front Genet       Date:  2022-05-30       Impact factor: 4.772

3.  Loss of RPS27a expression regulates the cell cycle, apoptosis, and proliferation via the RPL11-MDM2-p53 pathway in lung adenocarcinoma cells.

Authors:  Hongyan Li; Hong Zhang; Guomin Huang; Zhitong Bing; Duling Xu; Jiadi Liu; Hongtao Luo; Xiaoli An
Journal:  J Exp Clin Cancer Res       Date:  2022-01-24

Review 4.  RBM22, a Key Player of Pre-mRNA Splicing and Gene Expression Regulation, Is Altered in Cancer.

Authors:  Benoît Soubise; Yan Jiang; Nathalie Douet-Guilbert; Marie-Bérengère Troadec
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.